GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Cambium Bio CMB.AX · AUD

Health Care · ASX · 🇦🇺 Australia

Compare

0.36

-10.00%

Close of 4 Nov 2026, in AUD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Cambium Bio

Its shares trade on ASX under the ticker CMB.AX. It has been listed since 19 September 2013. In the fiscal year to 30 June 2026, it reported revenue of A$641,638 and a net loss of A$4.1m. At that date it held total assets of A$3.8m and shareholders' equity of A$2.4m.

Regeneus Ltd. is regenerative medicine company. The firm uses stem cell technologies to develop a portfolio of novel cell-based therapies. The firm develops regenerative medicine products, including its two stem cell technologies, Progenza, which has been licensed to Kyocera for the treatment of knee osteoarthritis in Japan, and Sygenus, which is in pre-clinical-stage. Regenerative therapies seek to address unmet medical needs in the human health market, focusing on osteoarthritis, neuropathic pain, and various skin conditions, with its platform technologies Progenza and Sygenus. Progenza is a cellular therapy targeting pain and inflammation which uses Secretome to improve not only the resident tissue, but the Mesenchymal Signalling Cells (MSCs) themselves. Sygenus is a cell-free topical serum and gel treatment for pain and inflammation. Sygenus is a cell-free topical serum and gel treatment for pain and inflammation.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
19 Sept 2013

Leadership

Pay as last reported

  • Dr. Edmund WallerChairman of the Board, since 2024
  • Mr. Karolis RosickasChief Executive OfficerA$1.2m
  • Mr. Terence WaltsExecutive Director, since 2024
  • Dr. Charlotte MorganHead - Laboratory, Research and Development
  • Prof. Chandra BalaDirector
  • Mr. Li-chien ChiuDirector
  • Dr. Yu-Hung TsengNon-Executive Director
  • Dr. Denese MarksIndependent Non-Executive Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Progenza licensed to Kyocera for knee osteoarthritis treatment in Japan
  • Sygenus in pre-clinical stage for skin conditions and pain treatment
  • Regeneus focuses on regenerative medicine with stem cell technologies

Weaknesses

  • Progenza only licensed for knee osteoarthritis in Japan
  • Sygenus remains in pre-clinical stage without commercialization
  • Regeneus has no products in late-stage clinical development

Opportunities

  • Expansion of Progenza into other countries beyond Japan
  • Sygenus development for broader skin and pain applications
  • Regeneus could partner with more companies for product development

Threats

  • Competition from other regenerative medicine companies
  • Regulatory delays for Sygenus approval process
  • Progenza's limited market scope in Japan only

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.